Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

NCT02650999 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

CD19+ Diffuse Large B-cell Lymphomas
Follicular Lymphomas
Mantle Cell Lymphomas

Interventions

DRUG: Pembrolizumab

Sponsor

Abramson Cancer Center at Penn Medicine